IL17A and B-cell acute lymphoblastic leukemia: Moreover, the upregulation of AKT and IL17A enhances the daunorubicin resistance of B cell acute lymphoblastic leukemia (ALL) cells (55), suggesting that daunorubicin downregulates IL17A.